Cell-Free DNA Fragmentomics: The Novel Promising Biomarker

Int J Mol Sci. 2023 Jan 12;24(2):1503. doi: 10.3390/ijms24021503.

Abstract

Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry the genetic and epigenetic information of its origin tissues. However, cfDNA is the mixture of various cell fragments, and the efficient enrichment of cfDNA fragments with diagnostic value remains a great challenge for application in the clinical setting. Evidence from recent years shows that cfDNA fragmentomics' characteristics differ in normal and diseased individuals without the need to distinguish the source of the cfDNA fragments, which makes it a promising novel biomarker. Moreover, cfDNA fragmentomics can identify tissue origins by inferring epigenetic information. Thus, further insights into the fragmentomics of plasma cfDNA shed light on the origin and fragmentation mechanisms of cfDNA during physiological and pathological processes in diseases and enhance our ability to take the advantage of plasma cfDNA as a molecular diagnostic tool. In this review, we focus on the cfDNA fragment characteristics and its potential application, such as fragment length, end motifs, jagged ends, preferred end coordinates, as well as nucleosome footprints, open chromatin region, and gene expression inferred by the cfDNA fragmentation pattern across the genome. Furthermore, we summarize the methods for deducing the tissue of origin by cfDNA fragmentomics.

Keywords: applications; biomarker; cell-free DNA; fragmentomics; tissue-of-origin.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cell-Free Nucleic Acids* / genetics
  • Chromatin
  • Humans
  • Nucleosomes / genetics

Substances

  • Cell-Free Nucleic Acids
  • Biomarkers
  • Chromatin
  • Nucleosomes